Meryl Waldman
National Institutes of Health
Internal medicineImmunoglobulin ERenal functionAutoantibodyRandomized controlled trialIntensive care medicineAdverse effectImmunologyMembranous nephropathySystemic lupus erythematosusMinimal change diseaseFocal segmental glomerulosclerosisKidney diseaseNephrotic syndromeDiseaseProteinuriaAutoimmunityLipodystrophyPopulationMedicineBiologyImmune systemGastroenterology
Publications 35
#1Sriram Gubbi (NIH: National Institutes of Health)H-Index: 9
#2Katherine A. Araque (NIH: National Institutes of Health)H-Index: 5
Last. Joanna Klubo-Gwiezdzinska (NIH: National Institutes of Health)H-Index: 16
view all 12 authors...
#1Martin Windpessl (Johannes Kepler University of Linz)H-Index: 6
#2Annette Bruchfeld (Linköping University)H-Index: 31
Last. Andreas Kronbichler (University of Cambridge)H-Index: 24
view all 9 authors...
Patients with kidney diseases should be prioritized for COVID-19 vaccination and the available data suggest that replication-defective viral-vectored vaccines and mRNA vaccines are safe to use. As vaccine responses are likely to be lower in patients with kidney diseases than in the general population, highly potent vaccines should be preferred.
17 CitationsSource
#1Rishi R. Goel (NIH: National Institutes of Health)H-Index: 10
#2Shuichiro Nakabo (NIH: National Institutes of Health)H-Index: 10
Last. Sarthak Gupta (NIH: National Institutes of Health)H-Index: 11
view all 13 authors...
We report on patients with STAT3 loss-of-function (LOF) mutations who developed lupus-like autoimmunity. Immune dysregulation seen in STAT3 LOF patients suggests a susceptibility to systemic autoimmunity with important implications in monitoring and management of these patients.
4 CitationsSource
#1Meryl Waldman (NIH: National Institutes of Health)H-Index: 16
#2María José SolerH-Index: 18
Last. Paolo Cravedi (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 35
view all 27 authors...
The effects of SARS-CoV-2 infection on individuals with immune-mediated glomerulonephritis, who are often undergoing immunosuppressive treatments, are unknown. Therefore, we created the International Registry of COVID infection in glomerulonephritis (IRoc-GN) and identified 40 patients with glomerulonephritis and COVID-19 followed in centers in North America and Europe. Detailed information on glomerulonephritis diagnosis, kidney parameters, and baseline immunosuppression prior to infection were...
9 CitationsSource
#1Claudia Benedetti (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 3
#2Meryl Waldman (NIH: National Institutes of Health)H-Index: 16
Last. Paolo Cravedi (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 35
view all 5 authors...
Novel coronavirus disease 2019 (COVID-19) has become a worldwide emergency health problem. The disease occurs mostly in individuals between 30-79 years of age and 81% of cases are mild. However, it may result in progressive respiratory failure owing to alveolar damage and can be fatal in 3.6% of the cases. Direct viral injury, uncontrolled inflammation, and activation of coagulation and complement cascades are thought to participate in disease pathogenesis. Patients with COVID-19 often display k...
29 CitationsSource
#1Daniella M. Schwartz (NIH: National Institutes of Health)H-Index: 14
#2Sarah A. Blackstone (NIH: National Institutes of Health)H-Index: 2
Last. Amanda K. Ombrello (NIH: National Institutes of Health)H-Index: 17
view all 15 authors...
The anti-inflammatory protein A20, encoded by TNFAIP3 , is a ubiquitin-modifying enzyme that targets proinflammatory molecules, including those upstream of the transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). Patients with heterozygous loss-of-function TNFAIP3 mutations develop haploinsufficiency of A20 (HA20), a systemic autoinflammatory disease that can cause severe end-organ pathology.1–3 No available medication directly targets NF-κB signalling; th...
8 CitationsSource
#1Peter D. Burbelo (NIH: National Institutes of Health)H-Index: 38
#2Megha Joshi (Walter Reed National Military Medical Center)H-Index: 1
Last. Stephen W. Olson (Walter Reed National Military Medical Center)H-Index: 12
view all 7 authors...
BACKGROUND: Circulating serum autoantibodies against the M-type phospholipase A2 receptor (PLA2R-AB) are a key biomarker in the diagnosis and monitoring of primary membranous nephropathy (MN). However, little is known about the appearance and trajectory of PLA2R-AB before the clinical diagnosis of MN. METHODS: Using the Department of Defense Serum Repository, we analyzed PLA2R-AB in multiple, 1054 longitudinal serum samples collected before diagnosis of MN from 134 individuals with primary MN, 3...
18 CitationsSource
#1Ho Lim Lee (NIH: National Institutes of Health)H-Index: 1
#2Meryl Waldman (NIH: National Institutes of Health)H-Index: 16
Last. Rebecca J. Brown (NIH: National Institutes of Health)H-Index: 29
view all 7 authors...
CONTEXT: Patients with lipodystrophy have high prevalence of proteinuria. OBJECTIVE: To assess kidney disease in patients with generalized (GLD) versus partial lipodystrophy (PLD), and effects metreleptin on proteinuria in patients with lipodystrophy. DESIGN/SETTING/PATIENTS/INTERVENTION: Prospective, open-label studies of metreleptin treatment in patients with GLD and PLD at the National Institutes of Health, Bethesda, MD. OUTCOME MEASURES: 24-hour urinary albumin and protein excretion rates, e...
4 CitationsSource
#1Sarfaraz Hasni (NIH: National Institutes of Health)H-Index: 23
#2Sarthak Gupta (NIH: National Institutes of Health)H-Index: 11
Last. Juan Rivera (NIH: National Institutes of Health)H-Index: 68
view all 20 authors...
OBJECTIVE: Autoreactive IgE antibodies have been implicated in the pathogenesis of systemic lupus erythematosus (SLE). We hypothesize that omalizumab, a monoclonal antibody binding IgE, may improve SLE activity by reducing type I interferon (IFN) production by hampering plasmacytoid dendritic cells and basophil activation. This study was undertaken to assess the safety, tolerability, and clinical efficacy of omalizumab in mild to moderate SLE. METHODS: Sixteen subjects with SLE and a Systemic Lu...
17 CitationsSource
#1Pietro A. Canetta (Columbia University)H-Index: 21
#2Jonathan P. Troost (UM: University of Michigan)H-Index: 1
Last. Dawn ZinsserH-Index: 3
view all 232 authors...
There is scant literature describing the effect of glomerular disease on health-related quality of life (HRQOL). The Cure Glomerulonephropathy study (CureGN) is an international longitudinal cohort study of children and adults with four primary glomerular diseases (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy). HRQOL is systematically assessed using items from the Patient-Reported Outcomes Measurement Informative System (PROMIS). We asse...
10 CitationsSource